Disease · MONDO_0000873

lymphoblastic lymphoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. lymphoblastic lymphoma. Diseases, record MONDO_0000873. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000873

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: lymphoblastic lymphoma; Open Targets
Open Targets ID: MONDO_0000873; Open Targets
Other names: lymphoma, lymphoblastic, malignant, precursor cell lymphoblastic lymphoma, precursor lymphoblastic lymphoma; Open Targets
Disease Ontology: DOID:0080147; Disease Ontology
NCI Thesaurus: C9360; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 83 drugs, from ClinicalTrials.gov and DailyMed; Open Targets

Drugs83

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ASPARAGINASE	CHEMBL2108989	Enzyme	Approval	DailyMed	18	17	15	Drugs and targets
ASPARAGINASE ERWINIA CHRYSANTHEMI	CHEMBL1863514	Enzyme	Approval	ClinicalTrials.gov	5	5	5	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 3	ClinicalTrials.gov	39	39	39	Drugs and targets
CYTARABINE	CHEMBL803	Small molecule	Phase 3	ClinicalTrials.gov	36	36	35	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	30	30	29	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	29	29	29	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
MERCAPTOPURINE	CHEMBL1200751	Small molecule	Phase 3	ClinicalTrials.gov	20	20	18	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
DOXORUBICIN	CHEMBL53463	Small molecule	Phase 3	ClinicalTrials.gov	17	17	17	Drugs and targets

1 to 10 of 83

See all 83 drugs

Targets132

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TOP2A	DNA topoisomerase 2-alpha	9	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 3	https://conductscience.org/library/genes/7153	Drugs and targets
ABL1	Bcr/Abl fusion protein	5	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 3	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	5	Bcr/Abl fusion protein inhibitor	Phase 3	https://conductscience.org/library/genes/613	Drugs and targets
NR3C1	Glucocorticoid receptor	5	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	4	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets

1 to 10 of 132

See all 132 targets

Trials86

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00408005	Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma	Phase 3	1,895	2019-06-20	T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma	ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN HYDROCHLORIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, MERCAPTOPURINE, METHOTREXATE, NELARABINE, PREDNISONE, THIOGUANINE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT02112916	Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma	Phase 3	847	2022-02-23	Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia	BORTEZOMIB, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT00004228	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Phase 3	393	2013-12-05	Lymphoma	ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN HYDROCHLORIDE, DEXAMETHASONE, DOXORUBICIN HYDROCHLORIDE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, THIOGUANINE, VINCRISTINE SULFATE	Its record names the disease	ClinicalTrials.gov
NCT01574274	SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma	Phase 2	240	2022-09-10	Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma	ASPARAGINASE, CALASPARGASE PEGOL	Its record names the disease	ClinicalTrials.gov
NCT04145531	An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)	Phase 2/3	229	2023-11-18	Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia	ASPARAGINASE ERWINIA CHRYSANTHEMI, CRISANTASPASE	Its record names the disease	ClinicalTrials.gov
NCT00671658	Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia	Phase 2	220	2020-12-03	Leukemia, Acute Lymphoblastic Leukemia	ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, MESNA, METHOTREXATE, METHYLPREDNISOLONE, PEGFILGRASTIM, RITUXIMAB, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00002766	Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma	Phase 3	170	2016-02-22	Leukemia, Lymphoma	CYCLOPHOSPHAMIDE, CYTARABINE, DACTINOMYCIN, DAUNORUBICIN, DOXORUBICIN, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, MITOXANTRONE, PEGASPARGASE, PREDNISONE, SARGRAMOSTIM, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00873093	Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	Phase 2	148	2017-01-27	B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia	BORTEZOMIB	Its record names the disease	ClinicalTrials.gov
NCT00866749	Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma	Phase 2	120	2019-09-10	Lymphoblastic Leukemia, Lymphoblastic Lymphoma	ASPARAGINASE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, THIOGUANINE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT00890656	Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage	Phase 2	90	2011-08-23	Acute Lymphoblastic Leukemia	CYCLOPHOSPHAMIDE, CYTARABINE, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 86

See all 86 trials

Comparisons in its trials13

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
SC-PEG (Arm A) vs Oncaspar (Arm B): deaths from any cause	7 of 119	5 of 120	239	NCT01574274	Trial comparisons
SC-PEG (Arm A) vs Oncaspar (Arm B): serious adverse events	35 of 119	27 of 120	239	NCT01574274	Trial comparisons
SC-PEG (Arm A) vs Oncaspar (Arm B): Number of Participants With Asparaginase-Related Toxicity	41 of 109	43 of 114	223	NCT01574274	Trial comparisons
All-2 vs L-20: serious adverse events	39 of 81	33 of 89	170	NCT00002766	Trial comparisons
Ph+ Subjects vs Ph- Subjects: Number of Participants With Morphological Complete Response Rate	27 of 28	20 of 25	53	NCT03023046	Trial comparisons
Conventional Care vs Intensive Insulin: serious adverse events	9 of 25	10 of 26	51	NCT00500240	Trial comparisons
Hyper-CMAD + Rituximab vs Hyper-CMAD: Number of Patients With Complete Remission at One Year	12 of 15	13 of 16	31	NCT01319981	Trial comparisons
Stratum 1 With 50 mg/m^2 vs Stratum PK With 50 mg/m^2: Number of Participants With at Least Partial Response to Palbociclib	4 of 6	1 of 6	12	NCT03792256	Trial comparisons
Stratum 1 With 50 mg/m^2 vs Stratum PK With 50 mg/m^2: Frequency of Dose Limiting Toxicities of Palbociclib	1 of 6	0 of 6	12	NCT03792256	Trial comparisons
Stratum 1 With 50 mg/m^2 vs Stratum PK With 50 mg/m^2: Frequency of Adverse Events of Palbociclib	5 of 6	5 of 6	12	NCT03792256	Trial comparisons

1 to 10 of 13

See all 13 comparisons in its trials

Papers from its trials64

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36108304	RESULT	1	PubMed
34228505	RESULT	1	PubMed
33593877	RESULT	1	PubMed
26887549	RESULT	1	PubMed
24344215	RESULT	1	PubMed
23389497	RESULT	1	PubMed
22994934	RESULT	1	PubMed
22488718	RESULT	1	PubMed
21715318	RESULT	1	PubMed
20378563	RESULT	1	PubMed

1 to 10 of 64

See all 64 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000873

GET https://conductscience.org/api/diseases/v1/MONDO_0000873/drugs?page=2

API reference For AI assistants